FDA's New Inspection Model and AI Tools: What RA Teams Must Know

The FDA just announced two seemingly unrelated initiatives that will fundamentally reshape how manufacturers experience regulatory oversight. First, Commissioner Marty Makary introduced one-day inspectional assessments as part of a broader push to modernise enforcement. Second, the agency launched ELSA 4.0, an upgraded AI tool now available to all FDA staff, alongside completing its HALO data platform consolidation. These aren't isolated policy updates. They represent a coordinated shift toward data-driven, risk-based regulation that will accelerate decision cycles and raise the bar for compliance readiness. If your quality systems and submission strategies haven't evolved to match this pace, you're already behind.

The One-Day Inspection Model: Efficiency or Intensity?

The FDA's announcement of one-day inspectional assessments is being framed as an efficiency gain, allowing the agency to focus resources where they're most needed. Commissioner Makary's language is telling: this isn't about reducing oversight, it's about enhancing effectiveness. The traditional multi-day establishment inspection is being supplemented—not replaced—by targeted assessments that can be deployed more frequently and with surgical precision.

For manufacturers, this changes the calculus entirely. A one-day inspection doesn't mean less scrutiny; it means investigators will arrive with clearer hypotheses, armed with pre-inspection data analysis, and focused on specific risk areas. There's no warm-up day. No gradual rapport-building. The FDA will have already reviewed your 510(k) submissions, post-market surveillance reports, adverse event data, and potentially even your website claims before the inspector walks through your door. The inspection starts the moment they identify you as a target, not when they arrive on-site.

This model demands a fundamentally different state of readiness. Your quality system can't be something you 'tidy up' before an audit. It must be inspection-ready at all times, with every CAPA genuinely closed, every risk assessment current, and every claim substantiated. The compressed timeline also means investigators will likely rely more heavily on document sampling and data analytics rather than exhaustive walkthroughs. If your documentation is inconsistent, outdated, or buried in siloed systems, a single day will be enough to expose those gaps.

AI-Powered Regulatory Review: The ELSA 4.0 Reality

Simultaneously, the FDA has equipped its entire workforce—from scientific reviewers to field investigators—with ELSA 4.0, an enhanced AI tool designed to extract insights from the agency's consolidated HALO data platform. This isn't a pilot programme. It's a full deployment that gives every FDA employee access to pattern recognition, anomaly detection, and cross-referenced intelligence across submissions, inspections, and post-market data.

Think about what this means in practice. When a reviewer assesses your 510(k), they can instantly compare your clinical data, labelling, and risk analysis against hundreds of similar predicate devices. They can flag inconsistencies between what you claimed in your submission and what your website marketing suggests. They can identify whether your supplier has been cited in other manufacturers' warning letters. The consolidation of the HALO platform means this intelligence isn't fragmented across legacy databases—it's unified, searchable, and increasingly automated.

For Software as a Medical Device (SaMD) manufacturers particularly, this AI capability intersects with the practical challenges outlined in Greenlight Guru's recent discussion about integrating Jira and GitHub into quality management systems. If FDA reviewers can leverage AI to analyse your submission data, but your own development team is still copying and pasting Jira tickets into Word documents for regulatory purposes, there's a fundamental asymmetry. The regulator is operating with better data infrastructure than you are. That's not a sustainable position.

The Convergence: Data-Driven Oversight Meets Agile Development

These two developments converge around a central theme: the FDA is moving faster and using better data tools, and manufacturers must match that evolution. The one-day inspection model is only viable because the agency now has the data infrastructure to prepare effectively before arriving on-site. ELSA 4.0 and HALO enable investigators to conduct meaningful assessments in compressed timeframes because they're not starting from zero—they're starting from a pre-populated risk profile of your organisation.

This also connects to the broader FDA and CMS initiatives around accelerated access, including the TEMPO, RAPID, and real-time trials programmes. The agencies are building infrastructure to make faster decisions, but that speed depends on higher-quality, more accessible data from manufacturers. Real-time trial data, continuous integration of design controls, and API-connected post-market surveillance aren't optional enhancements—they're becoming the expected baseline. The FDA is essentially saying: if you want faster approvals and more flexible pathways, you need to provide real-time, high-integrity data that our systems can ingest and analyse.

For SaMD companies, this means your development stack and your QMS can no longer be parallel universes. The audit drill described in the Greenlight Guru piece—where quality professionals manually reformat Jira tickets weeks before a submission—is exactly the kind of friction that will slow you down in this new environment. If your source of truth is GitHub, but your DHF is a static Word document, you're introducing transcription errors, version control nightmares, and delays that regulators increasingly won't tolerate. Modern QMS platforms that natively integrate with development tools aren't just nice to have; they're strategic infrastructure that determines whether you can keep pace with regulatory expectations.

What This Means for Your Team

Regulatory and quality teams need to recalibrate their assumptions about inspection readiness and submission strategy. Here's what this operational shift demands in practical terms.

First, continuous compliance is no longer aspirational—it's essential. If the FDA can launch a one-day inspection with minimal notice, your quality system must be audit-ready every single day. This means CAPAs closed promptly, deviations investigated thoroughly and documented contemporaneously, and management reviews that actually review. Mock inspections should be unannounced internal exercises, not scheduled events where teams prepare for weeks.

Second, your data infrastructure needs urgent attention. If FDA reviewers have AI tools that can cross-reference your submission against all your previous interactions with the agency, your internal systems should be at least as capable. Can you instantly pull every claim you've ever made about a device across all marketing channels? Can you demonstrate traceability from a clinical claim in your IFU back to the specific study data and risk assessment that supports it? If these queries require manual searching across email, shared drives, and legacy databases, you have a structural vulnerability.

Third, for software-driven devices, the integration of development tools into your QMS is now a compliance imperative, not just an efficiency play. Regulators are looking for evidence of robust design controls, and if your development history lives in Jira and GitHub but your DHF is a manually curated document, you're creating both compliance risk and operational inefficiency. Modern eQMS platforms that offer native integrations or APIs to development tools allow you to maintain a single source of truth while automatically generating the audit trail regulators expect.

Fourth, reconsider how you prepare for submissions. The traditional model—where regulatory writes a submission document based on months-old data from engineering, clinical, and quality—is too slow and too error-prone when reviewers have AI tools that can spot inconsistencies instantly. Your submission process should pull from living, continuously updated systems of record. Clinical data, risk management files, design history, and post-market surveillance should feed submissions dynamically, not through manual copy-paste exercises.

UK and EU Perspectives: Will MHRA and Notified Bodies Follow?

While these are FDA initiatives, UK and EU regulatory bodies are watching closely. The MHRA has already signalled interest in innovative inspection methodologies and data-driven oversight, particularly post-Brexit as it seeks to establish its own regulatory identity. Notified bodies under EU MDR and IVDR face enormous backlogs and resource constraints, making shorter, more focused audits an attractive proposition—provided they have the data infrastructure to support them.

Manufacturers serving multiple markets should anticipate convergence. If one-day inspections prove effective for the FDA, expect similar models to emerge elsewhere. The underlying principle—risk-based, data-driven oversight that focuses resources on the highest-priority areas—is universally appealing to resource-constrained regulators. The technical infrastructure required to support this model (consolidated databases, AI-assisted review, API-connected post-market data) is exactly what EU MDR and IVDR are pushing manufacturers toward anyway through EUDAMED and post-market surveillance requirements.

Key Takeaways

• The FDA's one-day inspection model and ELSA 4.0 AI deployment represent a coordinated shift toward data-driven, risk-based oversight that demands continuous compliance readiness from manufacturers.
• Inspections will increasingly start with pre-inspection data analysis, meaning your quality system must be audit-ready at all times, not just when an inspection is scheduled.
• The FDA's AI tools now enable reviewers and investigators to cross-reference submissions, marketing claims, supplier data, and post-market surveillance in real time—manufacturers need equivalent internal data infrastructure to maintain consistency and avoid exposure.
• For SaMD manufacturers, integrating development tools like Jira and GitHub directly into your QMS is becoming a compliance necessity, not just an operational efficiency, as regulators expect real-time, traceable design controls.
• UK and EU regulators are likely to adopt similar models as they seek to improve efficiency and focus resources; manufacturers should prepare for global convergence around data-driven, continuous oversight.

Building Systems That Match Regulatory Velocity

The FDA's moves signal a broader trend: regulators are investing in infrastructure that enables faster, smarter decisions. They're building the data platforms, AI tools, and streamlined processes that allow them to scale oversight without proportionally scaling headcount. For manufacturers, this creates both pressure and opportunity. The pressure is obvious—regulators will expect better data, faster responses, and continuous compliance. The opportunity is that manufacturers who invest in modern quality infrastructure, integrated development and compliance systems, and real-time data accessibility will be rewarded with faster approvals, more predictable inspections, and competitive advantage.

This isn't about working harder. It's about building systems that match the velocity and sophistication of modern regulatory oversight. The days of treating compliance as a periodic scramble before submissions and audits are ending. The future belongs to manufacturers whose quality systems are so robust, so integrated, and so transparent that regulatory interactions become routine data exchanges rather than stressful events. At SMEDTEC, we're helping clients navigate this transition—not just understanding the regulatory requirements, but building the operational infrastructure that makes continuous compliance sustainable and competitive.